Using NF-κB as a molecular target for theranostics in radiation oncology research

Expert Review of Molecular Diagnostics

Volumn 12, Issue 2, 2012, Pages 139-146

  Liu, Yu Chang ^a   Chiang, I Tsang ^a   Hsu, Fei Ting ^a   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

chemoresistance; IKK inhibitor; molecular targeting; nanoparticle; NF kB; radioresistance; sorafenib

Indexed keywords

APOPTOSIS INHIBITOR; BARDOXOLONE METHYL; BENZO[A]PYRENE; BORTEZOMIB; CELL CYCLE PROTEIN; CURCUMIN; DOCETAXEL; GEMCITABINE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SORAFENIB; THALIDOMIDE;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; BIOLUMINESCENCE; CANCER CELL; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR STRESS SIGNAL; CHEMORADIOTHERAPY; CHROMOSOME ABERRATION; CHRONIC INFLAMMATION; CLINICAL PRACTICE; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISTANT METASTASIS; DNA BINDING; DNA DAMAGE; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IMAGING; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LARYNX CANCER; LIVER CELL CARCINOMA; LYMPHOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ULTRAVIOLET RADIATION; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-KAPPA B; PROGNOSIS; PYRIDINES; RADIATION ONCOLOGY; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

EID: 84863273256     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.2     Document Type: Review

References (79)

1. Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 109(Suppl.), S81-S96 (2002).
2. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 6(3), 203-208 (2004).
3. Lin Y, Bai L, Chen W, Xu S. The NF-kB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 14(1), 45-55 (2010).
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140(6), 883-899 (2010).
5. Karin M. Nuclear factor-kB in cancer development and progression. Nature 441(7092), 431-436 (2006). (Pubitemid 44050137)
6. Basseres DS, Baldwin AS. Nuclear factor-kB and inhibitor of kB kinase pathways in oncogenic initiation and progression. Oncogene 25(51), 6817-6830 (2006). (Pubitemid 44657854)
7. Karin M, Cao Y, Greten FR, Li ZW. NF-kB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2(4), 301-310 (2002). (Pubitemid 37328783)
8. Pikarsky E, Porat RM, Stein I et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007), 461-466 (2004). (Pubitemid 39329586)
9. Vainer GW, Pikarsky E, Ben-Neriah Y. Contradictory functions of NF-kB in liver physiology and cancer. Cancer Lett. 267(2), 182-188 (2008).
10. Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C. NF-kB regulation of endothelial cell function during LPS-induced toxemia and cancer. J. Clin. Invest. 116(11), 2955-2963 (2006). (Pubitemid 44684480)
11. Piret B, Schoonbroodt S, Piette J. The ATM protein is required for sustained activation of NF-kB following DNA damage. Oncogene 18(13), 2261-2271 (1999). (Pubitemid 29186927)
12. Magne N, Toillon RA, Bottero V et al. NF-kB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 231(2), 158-168 (2006). (Pubitemid 43038726)
13. Barre B, Coqueret O, Perkins ND. Regulation of activity and function of the p52 NF-kB subunit following DNA damage. Cell Cycle 9(24), 4795-4804 (2010).
14. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory kB kinases a and b in nuclear factor-kB-mediated chemoresistance to doxorubicin. Mol. Cancer Ther. 7(7), 1827-1835 (2008).
15. Wang W, Cassidy J. Constitutive nuclear factor-k B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br. J. Cancer 88(4), 624-629 (2003). (Pubitemid 36363374)
16. Yoshida K, Sasaki R, Nishimura H et al. Nuclear factor-kB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck 32(5), 646-655 (2010).
17. Mi J, Zhang X, Rabbani ZN et al. RNA aptamer-targeted inhibition of NF-k B suppresses non-small cell lung cancer resistance to doxorubicin. Mol. Ther. 16(1), 66-73 (2008).
18. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol. Cancer Ther. 8(4), 959-970 (2009).
19. Sandur SK, Deorukhkar A, Pandey MK et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kB activity. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 534-542 (2009).
20. Tsuboi Y, Kurimoto M, Nagai S et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kB activation in human glioma cell lines. J. Neurosurg. 110(3), 594-604 (2009).
21. Lee CT, Park MY, Kim DR et al. Blockade of NF-kB activation by IkBa gene therapy enhances radiation sensitivity and abolishes acquired resistance to radiation. Mol. Med. Report 2(3), 471-475 (2009).
22. Katsman A, Umezawa K, Bonavida B. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kB inhibitor DHMEQ. Curr. Pharm. Des. 15(7), 792-808 (2009).
23. Campbell KJ, O'Shea JM, Perkins ND. Differential regulation of NF-kB activation and function by topoisomerase II inhibitors. BMC Cancer 6, 101 (2006).
24. Blagosklonny MV, Bednarski BK, Baldwin AS Jr, Kim HJ. Addressing reported proapoptotic functions of NF-kB: targeted inhibition of canonical NF-kB enhances the apoptotic effects of doxorubicin. PLoS One 4(9), e6992 (2009).
25. Garg AK, Jhingran A, Klopp AH et al. Expression of nuclear transcription factor kB in locally advanced human cervical cancer treated with definitive chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 78(5), 1331-1336 (2010).
26. Abdel-Latif MM, O'Riordan JM, Ravi N, Kelleher D, Reynolds JV. Activated nuclear factor-k B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. Dis. Esophagus 18(4), 246-252 (2005). (Pubitemid 43904793)
27. Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kB signalling pathway and prognostic significance in prostate cancer. Br. J. Cancer 102(7), 1163-1173 (2010).
28. Ross JS, Kallakury BV, Sheehan CE et al. Expression of nuclear factor-kB and I kBa proteins in prostatic adenocarcinomas: correlation of nuclear factor-kB immunoreactivity with disease recurrence. Clin. Cancer Res. 10(7), 2466-2472 (2004). (Pubitemid 38445708)
29. Zhang Q, Helfand BT, Jang TL et al. Nuclear factor-kB-mediated transforming growth factor-b-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin. Cancer Res. 15(10), 3557-3567 (2009).
30. Chung CH, Aulino J, Muldowney NJ et al. Nuclear factor-kB pathway and response in a Phase 2 trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 21(4), 864-870 (2010).
31. O'Neil BH, Funkhouser WK, Calvo BF et al. Nuclear factor k-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int. J. Radiat. Oncol. Biol. Phys. 80(3), 705-711 (2011).
32. Korkolopoulou P, Levidou G, Saetta AA et al. Expression of nuclear factor-kB in human astrocytomas: relation to pI kBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum. Pathol. 39(8), 1143-1152 (2008).
33. Zhang PL, Pellitteri PK, Law A et al. Overexpression of phosphorylated nuclear factor-k B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod. Pathol. 18(7), 924-932 (2005). (Pubitemid 41059953)
34. Jiang LZ, Wang P, Deng B et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-kB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum. Pathol. 42(8), 1185-1193 (2011).
35. Nariai Y, Mishima K, Yoshimura Y, Sekine J. FAP-1 and NF-kB expressions in oral squamous cell carcinoma as potential markers for chemo-radio sensitivity and prognosis. Int. J. Oral. Maxillofac. Surg. 40(4), 419-426 (2011).
36. Huang C, Huang K, Wang C et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol. Rep. 22(1), 89-95 (2009).
37. Li J, Jia H, Xie L et al. Association of constitutive nuclear factor-kB activation with aggressive aspects and poor prognosis in cervical cancer. Int. J. Gynecol. Cancer 19(8), 1421-1426 (2009).
38. Puvvada SD, Funkhouser WK, Greene K et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 78(3-4), 181-188 (2010).
39. Kleinberg L, Dong HP, Holth A et al. Cleaved caspase-3 and nuclear factor-kB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum. Pathol. 40(6), 795-806 (2009).
40. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for phosphorylated AKT and nuclear factor-kB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int. 58(12), 749-756 (2008).
41. Izzo JG, Wu X, Wu TT et al. Therapy-induced expression of NF-kB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis. Esophagus 22(2), 127-132 (2009).
42. Gilmore TD, Garbati MR. Inhibition of NF-kB signaling as a strategy in disease therapy. Curr. Top Microbiol. Immunol. 349, 245-263 (2011).
43. Shen HM, Tergaonkar V. NFkB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14(4), 348-363 (2009).
44. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kB pathways. Nat. Rev. Drug Discov. 7(12), 1031-1040 (2008).
45. Li F, Sethi G. Targeting transcription factor NF-kB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 1805(2), 167-180 (2010).
46. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kB pathway by direct inhibition of IKKb on Cys-179. J. Biol. Chem. 281(47), 35764-35769 (2006). (Pubitemid 46041307)
47. Molckovsky A, Siu LL. First-in-class, first-in-human Phase 1 results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting. J. Hematol. Oncol. 1(1), 20 (2008).
48. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kB activation through inhibition of IkBa kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and Cyclin D1. Carcinogenesis 24(7), 1269-1279 (2003). (Pubitemid 36927068)
49. Kanai M, Yoshimura K, Asada M et al. A Phase 1/2 study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 68(1), 157-164 (2011).
50. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer 62(8), 1137-1141 (2010).
51. Sethi G, Tergaonkar V. Potential pharmacological control of the NF-kB pathway. Trends Pharmacol. Sci. 30(6), 313-321 (2009).
52. Knisely JPS, Berkey B, Chakravarti A et al. A Phase 3 study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int. J. Radiat. Oncol. Biol. Phys. 71(1), 79-86 (2008).
53. Ch'ang HJ, Hsu C, Chen CH, Chang YH, Chang JS, Chen LT. Phase 2 study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82(2), 817-825 (2011).
54. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin. Cancer Res. 16(16), 4094-4104 (2010).
55. Pugh TJ, Chen C, Rabinovitch R et al. Phase 1 trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int. J. Radiat. Oncol. Biol. Phys. 78(2), 521-526 (2010).
56. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11(3), 239-253 (2011).
57. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin. Genitourin. Cancer 5(4), 291-294 (2007). (Pubitemid 46867367)
58. Hsieh CH, Jeng KS, Lin CC et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin. Drug Invest. 29(1), 65-71 (2009).
59. Horgan AM, Dawson LA, Swaminath A, Knox JJ. Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J. Gastrointest. Cancer doi:10.1007/s12029-010-9194-4 (2010) (Epub ahead of print).
60. Echeverria V, Burgess S, Gamble-George J et al. Sorafenib inhibits nuclear factor kB, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 162(4), 1220-1231 (2009).
61. Wu JM, Sheng H, Saxena R et al. NF-kB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 278(2), 145-155 (2009).
62. Suen AW, Galoforo S, Marples B et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 213-220 (2010).
63. Kuo YC, Lin WC, Chiang IT et al. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kB expression in vitro and in vivo. Biomed. Pharmacother. 66(1), 12-20 (2011).
64. Hainsworth JD, Ervin T, Friedman E et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116(15), 3663-3669 (2010).
65. Girard N, Mornex F. Sorafenib and radiotherapy association for hepatocellular carcinoma. Cancer Radiother. 15(1), 77-80 (2011).
66. Jenkins GJ, Mikhail J, Alhamdani A et al. Immunohistochemical study of nuclear factor-kB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J. Clin. Pathol. 60(11), 1232-1237 (2007). (Pubitemid 350084544)
67. Du J, Huo J, Shi J et al. Polymorphisms of nuclear factor-kB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens. Haematologica 96(5), 729-737 (2011).
68. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kB associated cytokines: TNF-a, IL-1a, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol. Carcinog. 44(2), 77-82 (2005). (Pubitemid 41397172)
69. Liu Z, Cheng M, Cao M. Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma. Biomed. Imag. Interv. J. 7(1), e5 (2011).
70. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomed. 3(2), 137-140 (2008). (Pubitemid 351611851)
71. Hamoudi RA, Appert A, Ye H et al. Differential expression of NF-kB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 24(8), 1487-1497 (2010).
72. Metelev V, Zhang S, Tabatadze D, Bogdanov A. Hairpin-like fluorescent probe for imaging of NF-kB transcription factor activity. Bioconjug. Chem. 22(4), 759-765 (2011).
73. Ho TY, Chen YS, Hsiang CY. Noninvasive nuclear factor-kB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. Biomaterials 28(30), 4370-4377 (2007).
74. Vykhovanets EV, Maclennan GT, Vykhovanets OV, Cherullo EE, Ponsky LE, Gupta S. Molecular imaging of nuclear factor-kB in bladder as a primary regulator of inflammatory response. J. Urol. 187(1), 330-337 (2012).
75. Mumm JB, Oft M. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 27(45), 5913-5919 (2008).
76. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1), 1-14 (2007). (Pubitemid 46537674)
77. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol. 26(14), 2405-2406 (2008).
78. Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 21(2), 206-209 (2010).
79. Mohiuddin MM, Harmon DC, Delaney TF. Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report. J. Chemother. 17(3), 343-346 (2005). (Pubitemid 40992276)